The seminal discovery of increased VEGF levels in ocular fluids of patients with retinal eye diseases (Adamis et al., 1994) introduced an era of anti-VEGF therapy in diseases such as DR, retinal vascular occlusions, retinopathy of prematurity (ROP), neovascular AMD and others. This evidence concerns the gene VEGFA and retinopathy of prematurity.